Evidence map›Paper›PMID 31519178›Full record

ArticleJournal of neuroinflammation2019

Long-term use of interferon-β in multiple sclerosis increases Vδ1

Guzailiayi Maimaitijiang, Mitsuru Watanabe, Koji Shinoda, Noriko Isobe, Yuri Nakamura, Katsuhisa Masaki, Takuya Matsushita, Yasunobu Yoshikai, Jun-Ichi Kira

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Choroid plexus epithelium and its role in neurological diseases.Frontiers in molecular neuroscience · 2022
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Guzailiayi MaimaitijiangDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Mitsuru WatanabeDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Koji ShinodaDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Noriko IsobeDepartment of Neurological Therapeutics, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yuri NakamuraDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Katsuhisa MasakiDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Takuya MatsushitaDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yasunobu YoshikaiDivision of Host Defense, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Jun-Ichi KiraDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. kira@neuro.med.kyushu-u.ac.jp.
Kyushu University · JP

Funding

Japanese Multiple Sclerosis Society N/AJapan Society for the Promotion of Science 15K09341Japan Society for the Promotion of Science 16H02657Japan Society for the Promotion of Science 17K16124Japan Society for the Promotion of Science 17K16125Japan Society for the Promotion of Science 18K07529Ministry of Health, Labour and Welfare H26-Nanchitou (Nan)-Ippan-043Ministry of Health, Labour and Welfare H29-Nanchitou (Nan)-Ippan-043
6 · The paper itself

Abstract

backgroundWe previously reported that Vδ2

methodsComprehensive flow cytometric immunophenotyping was performed in 35 untreated MS and 21 MS patients on IFN-β for more than 2 years (IFN-β-treated MS) including eight super-responders fulfilling no evidence of disease activity criteria, and 44 healthy controls (HCs).

resultsThe percentages of Vδ2

conclusionsThe present study suggests that long-term usage of IFN-β increases Vδ1

Indexed as

AdultFemaleHumansImmunologic FactorsInterferon-betaMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingReceptors, Antigen, T-Cell, gamma-deltaT-Lymphocyte SubsetsImmunologic FactorsInterferon-betaReceptors, Antigen, T-Cell, gamma-deltaDisease-modifying therapyInterferon-βMultiple sclerosisγδ T cell

Identifiers

PMID31519178
PMCPMC6743159
OpenAlexW2972837363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.